ArticleDrug safety2012
Focusing on risk communication about medicines: why now?
Article in Drug safety, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Strategies to enhance risk communication about medicines in Malaysia: a Delphi study among multinational experts.BMC health services research · 2024Article
- Review
- Enhancing medication risk communication in developing countries: a cross-sectional survey among doctors and pharmacists in Malaysia.BMC public health · 2022Article
- A New Tool for an Awareness Plan Concerning Critical Issues, Needs and Attitudes of Citizens on the Use of Medicines.Healthcare (Basel, Switzerland) · 2021Article
- Diabetes patient's pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation.Therapeutic advances in drug safety · 2020Article
- Prescribing Variation in General Practices in England Following a Direct Healthcare Professional Communication on Mirabegron.Journal of clinical medicine · 2018Article
- An Update on ISoP Special Interest Groups (SIGs).Drug safety · 2018Article
- The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.Drug safety · 2015Article
- Pharmaceutical company perspectives on current safety risk communications in Japan.SpringerPlus · 2014Article
- Evaluating the health literacy burden of Canada's public advisories: a comparative effectiveness study on clarity and readability.Drug safety · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.